Gyre Therapeutics, INC

Gyre Therapeutics announced the appointment of three new directors to its Board, effective August 1, 2026, to enhance scientific, clinical, and operational expertise.

Gyre Therapeutics, Inc. has filed an amendment to its Form 8-K to include financial statements of Cullgen Inc. following their merger on May 4, 2026.

Gyre Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and key proposals were approved.

Gyre Therapeutics, Inc. has released an updated corporate presentation detailing its integrated biopharmaceutical strategy, pipeline advancements, and operational efficiencies.

Gyre Therapeutics showcased preclinical data for its CDK2-cyclin E degrader, CG923308, targeting solid tumors and drug-resistant breast cancer.

Gyre Therapeutics announces China's NMPA has accepted the New Drug Application for F351 (hydronidone) for treating chronic hepatitis B-induced liver fibrosis.

Gyre Therapeutics reports a significant increase in Q3 2025 revenue and net income, driven by successful new product launches and strong ETUARY sales.

Gyre Therapeutics reported a decrease in Q2 revenue and net income, but significantly bolstered its cash reserves through a public offering and advanced key pipeline assets.

Gyre Therapeutics reports a decrease in Q1 2025 revenue compared to Q1 2024, but highlights strategic initiatives including the acquisition of Nintedanib and progress in clinical trials.

Gyre Therapeutics reported a decrease in revenue for the third quarter of 2024, while highlighting strategic initiatives including new product acquisitions and clinical trial advancements.

Gyre Therapeutics reported a net income of $14.5 million for the first six months of 2024, despite a decrease in revenue compared to the same period last year, primarily due to normalized anti-fibrosis drug sales.

Gyre Therapeutics reported a net income of $9.9 million for the first quarter of 2024, driven by increased sales of its key product, ETUARY.

Gyre Therapeutics reports increased revenue in 2025 driven by new product launches and positive Phase 3 Hydronidone results, while announcing a merger with Cullgen Inc.

Gyre Therapeutics reports a net income of $17.9 million for FY2024, driven by ETUARY sales and advancements in its F351 clinical program.

Gyre Therapeutics' 10-K filing outlines the company's share structure, dividend history, and strategic focus on developing anti-fibrotic drugs.

Gordon Carmichael, a Director at Gyre Therapeutics, Inc., has acquired stock options for 40,000 shares.

David M. Epstein, a Director at Gyre Therapeutics, Inc., has acquired 40,000 stock options with an exercise price of $5.95.

Gyre Therapeutics Director Dan Weng acquired 40,000 stock options with an exercise price of $5.95, vesting over 12 months.

Renate Parry, a Director at Gyre Therapeutics, Inc., has acquired 40,000 stock options with an exercise price of $5.95, vesting over 12 months.

Ping Zhang, a Director at Gyre Therapeutics, Inc., has acquired stock options for 40,000 shares, with vesting scheduled over 12 months.

Rodney L. Nussbaum, a Director at Gyre Therapeutics, Inc., was granted 40,000 stock options with an exercise price of $5.95.

Gyre Therapeutics schedules its 2026 Annual Meeting for June 10, 2026, to vote on director elections, executive compensation, auditor ratification, and the conversion of Series B Preferred Stock related to the Cullgen merger.

Gyre Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Gyre Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors, approve executive compensation, and ratify the appointment of its independent auditor.

Gyre Therapeutics, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Gyre Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on director elections, executive compensation, auditor ratification, and an amendment to the company's Certificate of Incorporation.

Gyre Therapeutics, Inc. has finalized its acquisition of Cullgen Inc. in an all-stock transaction valued at approximately $300 million, with a shareholder meeting scheduled for June 10, 2026, to approve the conversion of Series B Preferred Stock.

Gyre Therapeutics has finalized its all-stock merger with Cullgen Inc., resulting in significant ownership changes and the issuance of new convertible preferred stock.

Gyre Therapeutics has finalized its $300 million all-stock acquisition of Cullgen Inc., significantly expanding its corporate footprint.